ESR1 and breast carcinoma: Other ESR1 targets, such as lasofoxifene and H3B-5942, have proved superior to fulvestrant in inhibiting metastatic processes in breast cancer xenografts harboring Y537S and D538G ESR1 mutants [73,74].